呼吸道融合病毒（RSV）预防药:8市场医药品的预测与市场的分析 - 修订版

在八大主要市场中，RSV 预防市场预计到 2030 年将达到 72 亿美元，2020 年至 2030 年的复合年增长率为 28.6%。 2020 年，RSV 预防市场规模为 5.82 亿美元，所有销售额均来自阿斯特捷利康/艾伯维的 Synagis（帕利珠单抗）。 Synagis 是一种单株抗体 (mAb)，适用于高风险婴幼儿。近年来，呼吸道合胞病毒 (RSV) 预防药物市场显着成长，产品也更加多样化。两种单株抗体药物（阿斯特捷利康/赛诺菲的 Beyfortus (nirsevimab) 和默克公司的 Enflonsia (clesrovimab)）以及首批呼吸道合胞病毒 (RSV) 疫苗相继上市：葛兰素史克的 Arexvy、辉瑞的 Abrysvo 和 Moderna 的 mRESVIA。此外，五种处于后期研发阶段的疫苗也有望推动市场成长：葛兰素史克的 GSK-3888550A、AdVaccine 的 BARS-13 以及赛诺菲的 SP-0256、SP-0274 和 SP-0125。

本报告分析了八个主要的呼吸道合胞病毒 (RSV) 预防药物市场（美国、五个欧洲国家、日本和澳洲），并提供了疾病概况、流行病学、现有治疗方案、未满足的需求和机会以及研发策略等方面的资讯。

目录

第一章：呼吸道合胞病毒 (RSV) 预防药物：执行摘要 - 更新于 2025 年 7 月，基于截至 2025 年 7 月的事件

• 变更摘要
• RSV 预防药物市场预计到 2030 年将达到 72 亿美元
• 儘管新产品不断涌入，但仍存在未满足的需求
• 强大的后期研发管线持续丰富预防方案
• 医生的看法

第二章：引言 - 更新于 2025 年 7 月，基于截至 2025 年 7 月的事件

第三章：疾病概述 - 更新于 2024 年 11 月，基于截至 11 月的事件2024

• 病因与病理学
  • 病因
  • 病理学

第4章 流行病学，基于截至2021年8月的事件，于2021年8月更新

• 疾病背景
  • 危险因子和合併症
• 过去的全球趋势
• 预测方法
• 呼吸道合胞病毒 (RSV) 预防族群的流行病学预测（2020-2030 年）
  • 以胎龄划分的早产儿数量
  • 患有慢性肺部疾病 (CLD) 的早产儿
  • 患有血流动力学显着的心臟和先天性肺部疾病的出生数量
  • 患有DMD
  • SMA 患者人数
  • 妊娠晚期孕妇人数
  • 疗养院/长期照护机构成年住民人数
• 讨论
  • 流行病学预测考量
  • 分析的局限性
  • 分析的优势

第5章 疾病管理 - 更新于 2025 年 7 月，基于截至 2025 年 7 月的事件

• 诊断
• 预防
• 治疗
• KOL 对疾病管理的洞察

第6章 目前的治疗方案 - 更新于 2025 年 7 月，基于截至 2025 年 7 月的事件2025

• 概要

第7章 评估未满足的需求和机会 - 更新于2025年7月，基于截至2025年7月的事件

• 摘要
• 加强诊断检测
• 加强长期后遗症的研究与认知
• 联合疫苗
• 免疫功能低下患者的预防性治疗

第8章 研发策略 - 更新于2025年7月，基于截至2025年7月的活动

• 概述
  • 利用新的疫苗技术和策略
  • 开发具有改良剂量和剂量的保护性抗体疗效
• 临床试验设计
  • 用于母体免疫的呼吸道合胞病毒预防药物临床试验设计
  • 用于儿科免疫的呼吸道合胞病毒预防药物临床试验设计
  • 成人免疫的呼吸道合胞病毒预防药物临床试验设计

第9章 研发管线评估 - 更新于2025年7月，基于截至2025年7月的事件

• 概述
• 临床开发中的有前景的药物

第10章 研发管线评估分析 - 更新于2025年7月，根据截至2025年7月的事件2025

• 概述
• 竞争力评估
  • 孕产妇疫苗产品管线
  • 成人疫苗产品管线

第11章 现有及未来公司 - 更新于2025年7月，基于截至2025年7月的事件

• 概要
• 交易趋势

第12章 市场展望 - 更新于2025年7月，基于截至2025年7月的事件

• 全球市场
  • 预测
  • 促进因素与阻碍
• 美国
  • 预测
  • 主要的事件
  • 促进因素与阻碍
• 5EU
  • 预测
  • 主要的事件
  • 促进因素与阻碍
• 日本
  • 预测
  • 主要的事件
  • 促进因素与阻碍
• 澳洲
  • 预测
  • 主要的事件
  • 促进因素与阻碍

第13章 附录

The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.

RSV is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) orthopneumovirus belonging to the Pneumoviridae family. The most common clinical scenario for RSV is an upper respiratory tract infection (URTI), which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between two to three months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which on rare occasions can progress to respiratory failure or death. RSV is also an important cause of hospitalizations and deaths in elderly adults.

Across the 8MM, GlobalData expects the RSV prophylaxis market to grow at a compound annual growth rate (CAGR) of 28.6% over the 2020-30 forecast period, reaching $7.2 billion by 2030. In 2020, the RSV prophylaxis market was valued at $582M, with all sales attributable to AstraZeneca/AbbVie's Synagis (palivizumab), a monoclonal antibody (mAb) indicated for use in high-risk infants. The RSV prophylaxis market has undergone significant growth and diversification in the following years owing to the launch of two more mAbs, AstraZeneca/Sanofi's Beyfortus (nirsevimab) and Merck &Co's Enflonsia (clesrovimab), as well as the first RSV vaccines, GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA. Five vaccines in late-stage development will also drive market growth. These are GSK's GSK-3888550A, AdVaccine's BARS-13, and Sanofi's SP-0256, SP-0274, and SP-0125.

Key Highlights

• Report deliverables include a Pdf report and an Excel-based forecast model
• Forecast includes the 8 major markets (8MM)
• Forecast covers the period 2020-2030

Scope

• Overview of RSV including etiology, pathophysiology and epidemiology.
• Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.
• RSV prophylaxis market outlook from 2020-2030, including annual cost of therapy per patient, and total sales revenues per product for each of the 8MM.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM RSV prophylaxis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM RSV prophylaxis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Respiratory Syncytial Virus Prophylaxis: Executive Summary - Updated July 2025, based on events up to July 2025

• 1.1 Summary of changes
• 1.2 RSV prophylaxis market to reach $7.2 billion by 2030
• 1.3 Unmet needs remain despite influx of novel products
• 1.4 Prophylactic options to continue to diversify due to strength of late-stage pipeline
• 1.5 What do physicians think?

2 Introduction - Updated July 2025, based on events up to July 2025

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview - Updated Nov 2024, based on events up to Nov 2024

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology

4 Epidemiology - Updated Aug 2021, based on events up to Aug 2021

• 4.1 Disease background
  • 4.1.1 Risk factors and comorbidities
• 4.2 Global and historical trends
• 4.3 Forecast methodology
  • 4.3.1 Sources
  • 4.3.2 Forecast assumptions and methods
• 4.4 Epidemiological forecast for RSV prophylactic population (2020-30)
  • 4.4.1 Number of preterm births by gestational age
  • 4.4.2 Preterm infants with CLD
  • 4.4.3 Number of live births with hemodynamically significant heart disease and congenital lung disease
  • 4.4.4 Diagnosed prevalent cases of DMD
  • 4.4.5 Diagnosed prevalent cases of SMA
  • 4.4.6 Number of third-trimester pregnant women
  • 4.4.7 Number of adults living in nursing homes/long-term care institutions
• 4.5 Discussion
  • 4.5.1 Epidemiological forecast insight
  • 4.5.2 Limitations of the analysis
  • 4.5.3 Strengths of the analysis

5 Disease Management - Updated July 2025, based on events up to July 2025

• 5.1 Diagnosis
• 5.2 Prophylaxis
• 5.3 Treatment
• 5.4 KOL insights on disease management

6 Current Treatment Options - Updated July 2025, based on events up to July 2025

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment - Updated July 2025, based on events up to July 2025

• 7.1 Overview
• 7.2 Increased diagnostic testing
• 7.3 Increased research and awareness of long-term sequelae
• 7.4 Combination vaccines
• 7.5 Prophylaxis for immunocompromised patients

8 R&D Strategies - Updated July 2025, based on events up to July 2025

• 8.1 Overview
  • 8.1.1 Leveraging novel vaccine technologies and strategies
  • 8.1.2 Development of prophylactic antibodies with improved dosing and efficacy
• 8.2 Clinical trial design
  • 8.2.1 Clinical trial design for RSV prophylactics for maternal immunization
  • 8.2.2 Clinical trial design for RSV prophylactics for pediatric immunization
  • 8.2.3 Clinical trial design for RSV prophylactics for adult immunization

9 Pipeline Assessment - Updated July 2025, based on events up to July 2025

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis - Updated July 2025, based on events up to July 2025

• 10.1 Overview
• 10.2 Competitive assessment
  • 10.2.1 Pipeline maternal vaccine products
  • 10.2.2 Pipeline vaccine products for adults

11 Current and Future Players - Updated July 2025, based on events up to July 2025

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook - Updated July 2025, based on events up to July 2025

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers
• 12.5 Australia
  • 12.5.1 Forecast
  • 12.5.2 Key events
  • 12.5.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary Research - KOLs interviewed for this report
• 13.5 Primary research - prescriber survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Epidemiology Reviewers
  • 13.6.5 Vice President of Disease Intelligence and Epidemiology
  • 13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence
• About GlobalData
• Contact Us